For
UK
audiences
The professional's guide to product selection
The professional's guide to product selection
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
For the maintenance treatment of COPD.
Avoid in the case of renal impairment, pregnancy or breast feeding.
Solution for injection
Solution for injection
200 mcg/1 ml, 10 ampoules
600 mcg/3 ml, 3 ampoules
600 mcg/3 ml, 10 ampoules
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Long-acting selective beta2 agonist with corticosteroid.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/125 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/250 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Long-acting selective beta2 agonist with long-acting muscarinic antagonist.
Adult: one inhalation twice daily.
Antimuscarinic bronchodilator.
• Over 18 years: by inhalation of powder, 375 mcg (1 inhalation), twice daily.
Short-acting selective beta2 agonist.
For acute bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: Initially 100–200 micrograms, up to 800 micrograms daily for persistent symptoms.
For prophylaxis of allergen- or exercise-induced bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: 200 micrograms.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Antimuscarinic bronchodilator.
• Over 18 years: by inhalation of powder, 375 mcg (1 inhalation), twice daily.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
In the case of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 micrograms every 4 hours and when required, hourly use is occasionally necessary.
In the case of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Acute bronchospasm by inhalation of nebulised solution
• Child under 5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Severe or life-threatening acute asthma
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.